Want to see ES:CBAV full AI Analyst Report?
Top Page
Clinica Baviera
(BME:CBAV)
Select Model
Select Model
Rating:78Outperform
Price Target:
€70.00
▲(20.27% Upside)
Action:Reiterated
Date:08/04/26
The score is driven primarily by strong financial performance (steady growth, solid profitability, strong cash generation, and significantly reduced leverage). Technicals are supportive with an established uptrend and positive momentum, though indicators are approaching overbought levels. Valuation is the main constraint, with a relatively high P/E only partly balanced by the dividend yield.
Positive Factors
Steady revenue growth
Consistent multi-year revenue growth (2021 €173M to 2025 €302M) reflects expanding clinic scale and rising patient volumes. That durable top-line expansion supports operating leverage, capacity utilization and pricing power, improving medium-term cash flow visibility if volume trends persist.
Negative Factors
Margin volatility
Recent TTM margin shifts versus 2025 indicate variability in gross and operating profitability. Persistent margin volatility can weaken earnings predictability and ROE, and may reflect structural mix changes, pricing pressure or cost dynamics that could persist for several quarters absent corrective action.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady revenue growth
Consistent multi-year revenue growth (2021 €173M to 2025 €302M) reflects expanding clinic scale and rising patient volumes. That durable top-line expansion supports operating leverage, capacity utilization and pricing power, improving medium-term cash flow visibility if volume trends persist.
Read all positive factors
Clinica Baviera (CBAV) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€997.77M
Dividend Yield2.58%
Average Volume (3M)2.20K
Price to Earnings (P/E)21.8
Beta (1Y)0.51
Revenue Growth10.89%
EPS Growth17.12%
CountryES
Employees2,009
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)2.79
Shares Outstanding16,307,580
10 Day Avg. Volume2,444
30 Day Avg. Volume2,202
Financial Highlights & Ratios
PEG Ratio2.92
Price to Book (P/B)7.52
Price to Sales (P/S)2.74
P/FCF Ratio17.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.86
Revenue Forecast (FY)€331.00M
Clinica Baviera Business Overview & Revenue Model
Company Description
Clínica Baviera, S.A., a healthcare provider, manages a substantial chain of ophthalmological centers. This organization dedicates itself to the comprehensive diagnosis, therapeutic intervention, and continuous monitoring of diverse ocular conditi...
How the Company Makes Money
Clinica Baviera primarily makes money by charging patients for ophthalmology procedures and related clinical services delivered through its owned/operated clinic network. Its main revenue stream is patient fees for elective vision-correction treat...
Clinica Baviera Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
88
Very Positive
Cash Flow
81
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 316.98M | 301.78M | 262.65M | 224.92M | 198.45M | 172.73M |
| Gross Profit | 260.38M | 127.08M | 232.08M | 197.85M | 172.95M | 151.25M |
| EBITDA | 91.60M | 106.14M | 78.11M | 67.22M | 56.15M | 53.49M |
| Net Income | 46.33M | 42.06M | 40.20M | 35.97M | 29.52M | 27.39M |
Balance Sheet | ||||||
| Total Assets | 254.84M | 247.51M | 211.95M | 178.64M | 150.10M | 133.81M |
| Cash, Cash Equivalents and Short-Term Investments | 51.59M | 50.32M | 38.58M | 51.24M | 38.99M | 32.27M |
| Total Debt | 9.90M | 69.16M | 63.47M | 47.41M | 47.81M | 51.56M |
| Total Liabilities | 142.63M | 136.55M | 113.59M | 86.37M | 81.74M | 78.42M |
| Stockholders Equity | 111.57M | 109.99M | 96.92M | 91.00M | 67.34M | 54.60M |
Cash Flow | ||||||
| Free Cash Flow | 48.46M | 46.47M | 36.25M | 35.13M | 39.35M | 36.28M |
| Operating Cash Flow | 78.89M | 76.48M | 62.76M | 57.81M | 53.38M | 46.86M |
| Investing Cash Flow | -21.05M | -27.88M | -20.90M | -44.31M | -12.56M | -17.08M |
| Financing Cash Flow | -36.54M | -36.10M | -39.91M | -24.37M | -31.45M | -30.80M |
Clinica Baviera Technical Analysis
Positive
58.20
Price Trends
57.89
Positive
55.09
Positive
51.30
Positive
Market Momentum
0.99
Negative
60.30
Neutral
74.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:CBAV, the sentiment is Positive. The current price of 58.2 is below the 20-day moving average (MA) of 59.20, above the 50-day MA of 57.89, and above the 200-day MA of 51.30, indicating a bullish trend. The MACD of 0.99 indicates Negative momentum. The RSI at 60.30 is Neutral, neither overbought nor oversold. The STOCH value of 74.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:CBAV.
Clinica Baviera Peers Comparison
UnderperformOutperform
Sector (55)
ES:CBAV
Clinica Baviera
60.80
17.74
41.19%
ES:ALM
Almirall
10.48
-0.47
-4.34%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.